Interferon

Type: Keyphrase
Name: Interferon
First reported Aug 31 2014 - Updated Sep 01 2014 - 1 reports

How the Ebola Virus Jams Immune System Signals and Kills

The largest Ebola outbreak in history has been making headlines for months. Health officials and government leaders from West Africa and well beyond have been left perpetually scrambling to get ahead of a disease still boasting a mortality rate near 50 ... [Published Motherboard Magazine - Aug 31 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Post-Laser Topical

Main Image:LASERING USA’s AnteAGE Serum and Accelerator speed healing following laser skin resurfacing with a combination of cytokines (immunoregulatory proteins including growth factors, interleukins and interferons) derived from cultured cells and known ... [Published MedEsthetics Magazine - Aug 29 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Has Gilead Sciences, Inc.'s Star Drug Already Peaked?

First, new prescriptions started to fall in March. And then, as you'd expect, total prescriptions, which includes refills, peaked a couple of months later. There isn't necessarily a direct correlation between prescriptions and sales because we don't know ... [Published Motley Fool - Aug 29 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

TLR Ligands Induce Antiviral Responses in Chicken Macrophages

by Neda Barjesteh, Shahriar Behboudi, Jennifer T. Brisbin, Alexander Ian Villanueva, Éva Nagy, Shayan SharifChicken macrophages express several receptors for recognition of pathogens, including Toll-like receptors (TLRs). TLRs bind to pathogen-associated ... [Published Plosone.org - Aug 28 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Primary-progressive MS: studies ongoing

One of the great disappointments of multiple sclerosis research is a lack of effective treatments for people with progressive forms of the disease. But attention is slowly focusing on this neglected area and some advances may be made soon. “Progressive” ... [Published MSology - Aug 28 2014]
First reported Aug 27 2014 - Updated Aug 28 2014 - 3 reports

Bristol-Myers’ hep C drug Daklinza approved in Europe

US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the European Commission has approved Daklinza (daclatasvir), a pan-genotypic NS5A replication complex inhibitor (in vitro), for use in combination with other medicinal products across genotypes ... [Published Pharma Letter - Aug 28 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Biogen Idec : PLEGRIDY™Peginterferon Beta-1a Approved in the US for the Treatment of Multiple Sclerosis

By a News Reporter-Staff News Editor at Heart Disease Weekly -- The FDA approval of PLEGRIDY is based on results from one of the largest pivotal studies of beta interferon conducted, ADVANCE, which involved more than 1,500 MS patients. ADVANCE was a ... [Published 4 Traders - Aug 28 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 2 reports

Asthma sufferers have new hope

Hunter researchers along with their UK-based counterparts have developed an anti-viral treatment designed to reduce asthma episodes triggered by the common cold. Hunter researchers along with their UK-based counterparts have developed an anti-viral treatment ... [Published Maitland Mercury - Aug 27 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 2 reports

Gilead: Earnings Forecast Justifies $140 Price Target

By Leonard Yaffe :I have been recommending Gilead (NASDAQ: GILD ) for the past 3 years, and for the past 2 years my price target has been $140. Below, I shall discuss the company's current earnings stream, largely driven by Hepatitis C , as well as a ... [Published BioPortfolio - Aug 26 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Bilateral Retrobulbar Optic Neuropathy in the Setting of Interferon Alpha-2a Therapy

The development of biopharmaceutical agents, including the interferons (IFN), offers new treatment options for a wide range of medical conditions. Such advancements, however, have not come without risk to patients. Optic neuropathy in the setting of IFN ... [Published Sexual Development - Aug 26 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Method of treating viral diseases

A medicament based on antibodies contains an activated form of monoclonal, polyclonal, or natural antibodies to interferon in low or ultra-low doses prepared by multiple consecutive dilutions and exposure to external factors, preferably in accordance ... [Published Free Patents Online - Aug 26 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Methods for treating Friedreich's ataxia with interferon gamma

Described herein are compositions and methods for treating Friedreich's Ataxia (FRDA) with interferon gamma. In some aspects, methods for increasing expression of frataxin in cells and for treating Friedreich's Ataxia are provided. In some additional ... [Published Free Patents Online - Aug 26 2014]

Quotes

"The NHS guidelines are clear to me; neurologists in England and Wales can prescribe interferon-beta, but not glatiramer acetate, for patients with CIS provided they have (1) an abnormal MRI that predicts a high likelihood of recurrent episodes, (2) had a discussion with the patient about the benefits and risks of treatment and (3) start the interferon within 12 months of the clinical attack. The guidelines are not too prescriptive and allow the neurologist to make his/her call on what constitutes an abnormal MRI that predicts a high likelihood of recurrent episodes."
...stress, microgravity, altered sleep cycles and isolation could all have an effect on crew member immune systems," he said in a NASA news release. "If this situation persisted for longer deep space missions, it could possibly increase risk of infection, hypersensitivity, or autoimmune issues for exploration astronauts."
...price is "restrictive" as NGOs say they do not have the capacity to scale up treatment to thousands who will need the pills in the coming years. "The number of people who are going to get sick or die due to liver disease is expected to keep rising in India as HCV infections acquired years ago are increasingly taking their toll. Though treatment is improving dramatically with the new oral medications which have high cure rates, the Indian health ministry lacks strategy. They are facing multiple hurdles here in India to access these new oral drugs — from apathy to fast-track registration to intellectual property barriers" Leena Menghaney of MSF, an international medical humanitarian organization, said
"The presence of current heavy alcohol use (>14 drinks per week for men or >7 drinks per week for women), binge alcohol use (>4 drinks per occasion at least once a month), and/or active injection drug use and/or other illicit drug use as documented with a positive urine toxicology screen requires referral to treatment of substance use disorder (preferably to an addiction treatment specialist) before HCV treatment initiation. Patients with a substance abuse disorder must be actively participating in treatment for the disorder or be abstinent for 6 months prior to the initiation of HCV treatment."

More Content

All (637) | News (489) | Reports (0) | Blogs (142) | Audio/Video (0) | Fact Sheets (3) | Press Releases (2)
sort by: Date | Relevance
Sofosbuvir and vedolizumab knocked back [Published Gastroenterology Update - 5 hours ago]
TLR sorting by Rab11 endosomes maintains intest... [Published EMBO Journal - 20 hours ago]
New Summary: Clinical Pharmacogenetics Implemen... [Published National Guideline Clearinghouse - 22 hours ago]
Health Tip: Take it Easy After Blood Donation [Published Drugs.com - 22 hours ago]
Five Questions With: Dr. Lynn Taylor [Published Providence Business News - Sep 01 2014]
Surgery remains ‘gold standard’ for basal cell ... [Published Orthopedics Today - Sep 01 2014]
ClinicSpeak: Are you confused about DMTs prescr... [Published Multiple Sclerosis Research - Sep 01 2014]
How the Ebola Virus Jams Immune System Signals ... [Published Motherboard Magazine - Aug 31 2014]
Whidbey pot grower claims he’s developed benefi... [Published Whidbey News-Times - Aug 30 2014]
Hepatitis C [Published Newmarket Journal - Aug 30 2014]
Spaceflight Might Weaken Astronauts' Immune Sys... [Published Bio-Medicine - Aug 29 2014]
Identification of Toll-Like Receptor 9 as Parap... [Published Plosone.org - Aug 29 2014]
Health Tip: Exercise While Watching Television [Published Drugs.com - Aug 29 2014]
Materials and methods for prevention and treatm... [Published PharmCast - Aug 29 2014]
Post-Laser Topical [Published MedEsthetics Magazine - Aug 29 2014]
Has Gilead Sciences, Inc.'s Star Drug Already P... [Published Motley Fool - Aug 29 2014]
Bristol-Myers' Oral HCV Treatment Daklinza Gets... [Published Yahoo! Finance - Aug 28 2014]
Early Activation of MAP Kinases by Influenza A ... [Published Plosone.org - Aug 28 2014]
Hep C drugs face multiple hurdles [Published Times of India - Aug 28 2014]
Dengue Therapeutics, Chemoprophylaxis, and Alli... [Published Plosone.org - Aug 28 2014]
TLR Ligands Induce Antiviral Responses in Chick... [Published Plosone.org - Aug 28 2014]
Early Mucosal Sensing of SIV Infection by Panet... [Published Plosone.org - Aug 28 2014]
TLR2 Signaling Decreases Transmission of Strept... [Published Plosone.org - Aug 28 2014]
New Multiple Sclerosis Drug May Reverse Nerve D... [Published Pharmacy Times - Aug 28 2014]
New California HCV Treatment Restrictions.....r... [Published National AIDS Treatment Advocacy Project - Aug 28 2014]
NHS go ahead for new MS treatment [Published BootsWebMD - Aug 28 2014]
HCV Is Even More Dangerous During Menopause; CB... [Published SBWire - Aug 28 2014]
Health Tip: Recognizing Hay Fever [Published Drugs.com - Aug 28 2014]
Drug Repurposing [Published In the Pipeline - Aug 28 2014]
KuicK Research: Global Biosimilars Market Has 2... [Published BusinessWeek - Aug 28 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
ClinicSpeak: Are you confused about DMTs prescr... [Published Multiple Sclerosis Research - Sep 01 2014]
Who is responsible for keeping UK neurologists up-to-date about prescribing policy? #ClinicSpeak #MSBlog #MSResearch "Unfortunately, this post is for UK, and possibly English and Welsh,  MSers only. The MSer who contacted me last week about her frustrations ...
Drug Repurposing [Published In the Pipeline - Aug 28 2014]
A reader has sent along the question: "Have any repurposed drugs actually been approved for their new indication?" And initially, I thought, confidently but rather blankly, "Well, certainly, there's. . . and. . .hmm", but then the biggest example hit ...
Primary-progressive MS: studies ongoing [Published MSology - Aug 28 2014]
One of the great disappointments of multiple sclerosis research is a lack of effective treatments for people with progressive forms of the disease. But attention is slowly focusing on this neglected area and some advances may be made soon. “Progressive” ...
MOG extracellular domain (p1-125) triggers elev... [Published Multiple Sclerosis Journal current issue - Aug 26 2014]
Background: Myelin-specific T cells are implicated in multiple sclerosis (MS) and drive experimental autoimmune encephalomyelitis (EAE). EAE is commonly induced with short peptides, whereas in MS, whole myelin proteins are available for immune response. ...
Causes of Death in MSers [Published Multiple Sclerosis Research - Aug 26 2014]
What is the commonest cause of death in MS? #MSBlog #MSResearch "This US database study confirms that MS is responsible for excessive number of deaths and these are dominated by infections, particularly pulmonary infections as a result of aspiration. ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Hemispherx Biopharma and Bioclones Join Forces ... [Published GlobeNewswire: Acquisitions News - Jul 08 2014]
Simeprevir has now been approved in Russia [Published GlobeNewswire: Acquisitions News - Mar 24 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.